Retrospective analysis of trabectedin plus pegylated liposomal doxorubicin in patients with recurrent ovarian cancer

Trial Profile

Retrospective analysis of trabectedin plus pegylated liposomal doxorubicin in patients with recurrent ovarian cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin liposomal
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top